GlassScriptPhysician profile
Jay N Dolitsky
NPI 1649219783
$3,050.31
in general payments reported to CMS, 2019-2025
25 companies · $607 in 2025
The $607 reported for 2025 was more than what 81% of Pediatric Otolaryngology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $421 · 2021: $216 · 2022: $579 · 2023: $483 · 2024: $499 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $537.86 | 2019-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $458.54 | 2020-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $305.35 | 2020-2025 | |
| Optinose US, INC. | $273.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $173.16 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $140.61 | 2019-2020 | |
| Neurent Medical Limited | $122.75 | 2023-2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Stryker Corporation | $115.85 | 2022 | |
| Aerin Medical INC. | $107.42 | 2024-2025 | |
| Medtronic, INC. | $99.39 | 2023-2025 | Pteye Parathyroid Detection System, Sinuva, Stealthstation S8 Platform |
| Alk-Abello, INC | $93.98 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Hikma Pharmaceuticals USA | $85.66 | 2023-2024 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $70.66 | 2022 | |
| Integra Lifesciences Corporation | $58.83 | 2024-2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Smith+Nephew, INC. | $55.53 | 2022-2023 | Rapid Rhino, Tula, Coblation |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $52.07 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $50.96 | 2025 | Neffy |
| Amgen INC. | $49.59 | 2023 | Tezspire |
| Intersect Ent, INC. | $35.36 | 2020 | |
| Phadia US INC. | $34.20 | 2020-2024 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.15 | 2022 | |
| Acclarent, INC | $32.78 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $27.63 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $21.66 | 2022 | |
| Octapharma USA, INC. | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Dolitsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.